Ovid Therapeutics Inc. (OVID): who owns it and who trades it
As of Nov 16, 2026, OVID insiders reported 2 open-market sales worth $29.3K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Margaret A. Alexander (CEO), with $16.9K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Ovid Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns OVID
130 funds and institutions reported OVID shares worth $397M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Jupiter Topco LLC with 15.7%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Jupiter Topco LLC | 20.74M | 15.73% | $55.9M | – |
| Eventide Asset Management, LLC | 11.81M | 8.96% | $31.8M | +19% |
| BlackRock, Inc. | 10.82M | 8.21% | $29.1M | +606% |
| Ra Capital Management, L.P. | 10.50M | 7.96% | $28.2M | -2% |
| Affinity Asset Advisors, LLC | 10.14M | 7.69% | $27.3M | -5% |
| State Street Corp | 7.90M | 5.99% | $21.3M | +1419% |
| Vanguard Capital Management LLC | 7.76M | 5.88% | $20.9M | +48% |
| ADAR1 Capital Management, LLC | 7.42M | 5.62% | $20M | +63% |
| Balyasny Asset Management L.P. | 6.72M | 5.10% | $18.1M | +21% |
| Adage Capital Partners Gp, L.l.c. | 6.16M | 4.67% | $16.6M | No change |
| Federated Hermes, Inc. | 5.95M | 4.51% | $16M | +67% |
| Braidwell LP | 5.92M | 4.49% | $15.9M | – |
| Geode Capital Management, LLC | 4.07M | 3.09% | $11M | +209% |
| Silverarc Capital Management, LLC | 3.10M | 2.35% | $8.3M | +210% |
| Stempoint Capital LP | 2.42M | 1.83% | $6.5M | – |
| Ikarian Capital, LLC | 2.27M | 1.72% | $6.1M | -22% |
| Point72 Asset Management, L.P. | 1.95M | 1.48% | $5.2M | +47% |
| Sphera Funds Management Ltd. | 1.35M | 1.03% | $3.6M | -17% |
| Northern Trust Corp | 1.25M | 0.94% | $3.4M | +389% |
| Vanguard Fiduciary Trust Co | 1.14M | 0.87% | $3.1M | +65% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, OVID insiders reported $0 of open-market purchases and $29.3K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | Jeffrey A Rona | CBFO | Sale | 8,541 | $1.45 | $12.4K | Form 4 |
| Feb 23, 2026 | Margaret A. Alexander | CEO | Sale | 11,656 | $1.45 | $16.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Margaret A. Alexander | President and CEO, Director | – | $16.9K | Feb 23, 2026 |
| Jeffrey A Rona | CBFO | – | $12.4K | Feb 23, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
OVID short interest
Moderate short interest. 9.3% of OVID shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 80%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 18.13M OVID shares were sold short, 9.3% of the shares outstanding, up 0.4% from the report before. At the average daily volume of 2.21M shares, buying them all back would take about 8.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 18.13M | 9.29% | +0% | 2.21M | 8.2 |
| Oct 15, 2026 | 18.07M | 9.25% | -5% | 1.44M | 12.6 |
| Sep 30, 2026 | 18.95M | 9.70% | -10% | 2.12M | 8.9 |
| Sep 15, 2026 | 21.15M | 10.83% | +2% | 1.23M | 17.2 |
| Aug 31, 2026 | 20.67M | 10.59% | -4% | 1.58M | 13.1 |
| Aug 14, 2026 | 21.64M | 11.08% | +1% | 1.43M | 15.2 |
| Jul 31, 2026 | 21.46M | 16.28% | -3% | 1.53M | 14.0 |
| Jul 15, 2026 | 22.04M | 16.71% | +0% | 1.74M | 12.7 |
| Jun 30, 2026 | 22.00M | 16.68% | +86% | 5.82M | 3.8 |
| Jun 15, 2026 | 11.86M | 8.99% | +12% | 1.77M | 6.7 |
| May 29, 2026 | 10.63M | 8.06% | +5% | 1.26M | 8.4 |
| May 15, 2026 | 10.09M | 7.65% | +18% | 2.21M | 4.6 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Ovid Therapeutics company events
Ovid Therapeutics filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Jul 8, 2026LeadershipOvid Therapeutics Inc. and Jeffrey Rona, who served as the Company’s Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary, mutually agreed to Mr. Rona’s transition from such roles with the Company, effective July 6, 2026. Filing
- Jun 11, 2026VoteReported shareholder vote results. Filing
- Jun 3, 2026LeadershipThe Board of Directors of Ovid Therapeutics Inc. approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the appointment of Anna Greka, M.D., Ph.D., as a Class III director of the… Filing
- Apr 20, 2026AnnouncementThe Series A Warrants issued by Ovid Therapeutics Inc. in connection with its October 2025 private placement expired. Filing
- Mar 18, 2026AgreementOvid Therapeutics Inc. entered into a Securities Purchase Agreement with the purchasers named therein, pursuant to which the Company agreed to issue and sell an aggregate of 19,154,321 shares of its common stock, par value $0.001 per share, at a purchase price of $2.01 per share and, in lieu of… Filing
- Dec 18, 2025AnnouncementOvid Therapeutics Inc. issued a press release announcing results from its Phase 1 study of OV350. Filing
- Dec 11, 2025VoteReported shareholder vote results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Ovid Therapeutics financials
Famous investors that hold OVID
2 of the 50 well-known investors we track reported holding OVID in their latest 13F filing. The largest position is Steve Cohen's, worth $6.3M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 2.55M | $6.3M | 0.0% | +31% |
| Israel Englander · Millennium Management | Q3 2026 | 55,134 | $137K | 0.0% | +71% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named OVID in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G/A | 3.5% |
| Nov 16, 2026 | ADAR1 Capital Management, LLC | 13G/A | 3.5% |
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 7.8% |
| Nov 16, 2026 | RA Capital Management, L.P. | 13G/A | 7.8% |
Questions about Ovid Therapeutics Inc. (OVID) stock
Who owns the most OVID stock?
The largest reported owner of Ovid Therapeutics Inc. (OVID) is Jupiter Topco LLC, with 15.7% of the company. In total, 130 funds and institutions reported holding OVID at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are OVID insiders buying or selling?
In the last 12 months, OVID insiders reported no open-market purchases and 2 sales worth $29.3K. The latest trade was on Feb 23, 2026. See every trade.
What is the short interest in OVID?
As of Oct 30, 2026, 18.13M OVID shares were sold short, 9.3% of the shares outstanding, up 0.4% from the report before. At the average daily volume of 2.21M shares, buying them all back would take about 8.2 trading days (days to cover). See the history.
Which famous investors hold OVID?
2 of the 50 well-known investors we track reported OVID in their latest 13F filing, including Steve Cohen, Israel Englander. The largest position is worth $6.3M. See all holders.
Executive pay
Ovid Therapeutics's chief executive was paid a total of $1.9M for the year ended Dec 31, 2025, down 30% from $2.8M the year before. In the last 12 months, Ovid Therapeutics's executives and directors bought no stock on the open market and sold $29.3K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.